Tumor-Agnostic Therapies: Is The TAPUR Study Right For You?
Diagnosis and Treatment, Clinical Research, Research, Medical Community, Novel Treatments Our MBClife Diagnosis and Treatment, Clinical Research, Research, Medical Community, Novel Treatments Our MBClife

Tumor-Agnostic Therapies: Is The TAPUR Study Right For You?

For our Season 9 opening episode, we're learning about agnostic treatments in cancer with Dr. Richard Schilsky of ASCO, who discusses the  TAPUR Study. You may wonder, what is TAPUR and how does it relate to agnostic treatments?  The pioneer behind the study, Dr. Schilsky, explains clinical trials for agnostic therapeutics, how you can join a TAPUR trial, and what to expect.

Read More
Tumor-Agnostic Therapies: Is This a Paradigm Shift in Cancer Care?
Diagnosis and Treatment, Clinical Research, Research, Novel Treatments, Medical Community Our MBClife Diagnosis and Treatment, Clinical Research, Research, Novel Treatments, Medical Community Our MBClife

Tumor-Agnostic Therapies: Is This a Paradigm Shift in Cancer Care?

Do tumor-agnostic therapies represent a radical shift in oncology? Join us on this 1st part of a 2-part series as Dr. Joshua Drago of MSKCC answers this question and points out the advantages as well as the treatment limitations of agnostic therapeutics.

Read More
Road to a Cure - ADC & SARM
Novel Treatments, Medical Community, Challenges and Barriers, Health Disparities, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Immunotherapy, Difficult to Treat, Clinical Research, Long Term Adverse Effects Our MBClife Novel Treatments, Medical Community, Challenges and Barriers, Health Disparities, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Immunotherapy, Difficult to Treat, Clinical Research, Long Term Adverse Effects Our MBClife

Road to a Cure - ADC & SARM

How famous is Dr Hope Rugo? She belongs to a tiny elite group of oncologists who have their own Wikipedia page. Dr. Dennis Slamon is quite possibly the only other member. Enough said. No surprise that we can’t wait to hear what she has to say about a new class of drugs, known as ADCs and specifically, the first ADC for mTNBC that already has a nickname – Sassy (sacituzumab govitecan). Do you know what a SARM is? It is a special class of drugs for those who are Androgen Receptor (AR) positive. Listen and find out.

Read More